Khiron Life Sciences (CVE:KHRN) on Meeting UN Quotas to Supply Colombian Clinics

Khiron Life Sciences Corp (TSX-V:KHRN) (OTCQB:KHRNF) CEO Alvaro Torres joins Midas Letter to discuss completing the construction of their sophisticated medical cannabis processing facility and its capacity to produce commercial products. The GMP certified lab has microbiology and physical chemical analysis labs and also extraction capacity. Through scalable and flexible operations, Khiron has designed its cultivation capabilities to work within the most up-to-date country quota to meet Colombian demand, including serving more than 120,000 patients at the Company's IILANS clinics. The CEO also comments on construction of its Uruguay facility, which will act as an entryway to the Brazilian market.

Addressing the underwhelming financial performance of cannabis companies this quarter, the Khiron CEO comments:

"we all have to understand that this is a difficult market to begin. But we’ve been doing this for only a year and a half; we’re already generating $5 million in sales for the first half of the year, with the clinics and with Kuida."

************************

Check out our website:


************************

SUBSCRIBE to our YouTube:


SUBSCRIBE to our 2nd YouTube Channel - Midas Letter Clips:


SUBSCRIBE to our Newsletter:


Download Our Podcast on iTunes:


************************

Follow Us on Twitter:


Like Us on Instagram:


Like Us on Facebook:


************************

#WeedStocks
#MidasLetter

midas letter,midas letter live,economy,news,cannabis,investing,weed stocks,pot stocks,khiron,khiron life sciences,cve:khrn,colombia,united nations,clinic,